Eugene Reynolds, MD
Family Medicine · Gastonia, NCNPI 1518963594
Payments from drug & device makers
Across 193 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$942
- AbbVie$718
- Gilead$313
- Sanofi$255
- Merck$254
- Lilly USA, LLC$248
- plus $1K from 25 others
What the payments were for
- Consulting fees$200%
- Speaking & faculty fees$3479%
- Food & beverage$3,56789%
- Education$722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 43 | $942 |
| AbbVie | 33 | $718 |
| Gilead | 16 | $313 |
| Sanofi | 3 | $255 |
| Merck | 13 | $254 |
| Lilly USA, LLC | 13 | $248 |
| Pfizer | 11 | $169 |
| AstraZeneca | 9 | $153 |
| Novo Nordisk | 9 | $144 |
| Sanofi-aventis U.S. LLC | 2 | $92 |
| GSK | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $74 |
| Shield Therapeutics Inc | 4 | $74 |
| Johnson & Johnson(2 entities) | 4 | $63 |
| Theratechnologies Inc. | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Exact Sciences | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 3 | $35 |
| Boehringer Ingelheim | 2 | $29 |
| Novartis | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Bayer | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $17 |
| Edwards Lifesciences | 1 | $17 |
| Amgen | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Napo Pharmaceuticals Inc | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$110
How this compares
$4,006 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 74 | $303,513 |
| MounjaroTirzepatide | 182 | $206,190 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 37 | $145,957 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 33 | $128,331 |
| EliquisApixaban | 167 | $120,050 |
| JardianceEmpagliflozin | 98 | $89,862 |
| XifaxanRifaximin | 23 | $88,689 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $85,996 |
| JulucaDolutegravir/Rilpivirine | 24 | $84,621 |
| LinzessLinaclotide | 69 | $53,368 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $46,713 |
| MyrbetriqMirabegron | 101 | $46,492 |
| OzempicSemaglutide | 33 | $39,723 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $36,526 |
| ZenpepLipase/Protease/Amylase | 12 | $34,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $313 | $449,470111 claims |
| Lilly USA, LLCMounjaro, Trulicity | $248 | $240,504206 claims |
| Viiv Healthcare CompanyTriumeq, Juluca | $942 | $212,95257 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat | $29 | $129,481150 claims |
| PfizerEliquis | $169 | $120,050167 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $78 | $101,391151 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $54 | $88,68923 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $153 | $59,818111 claims |
| AbbVieLinzess | $718 | $53,36869 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $46,492101 claims |
| Novo NordiskOzempic | $144 | $39,72333 claims |
| Johnson & JohnsonXarelto | $63 | $30,62330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Gastonia
- Steve VacalisGastonia$693K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.